Wilmington, MA, United States of America

Andrew Leduc

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Karyopharm Therapeutics Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Leduc. Retrieved from https://idiyas.com/inventor/andrew-leduc

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Andrew Leduc: Inventor in Wilmington, Massachusetts.

Introduction

Andrew Leduc is an inventor based in Wilmington, Massachusetts, whose patent work includes methods for synthesizing heteroaryl derivatives of triazolyl acrylamides and preparing crystalline forms of a related compound. He is associated with Karyopharm Therapeutics Inc.

Latest Patents

Leduc is named on 1 patent: “Methods of Synthesis of Heteroaryl Derivatives of Triazolyl Acrylamides and Crystalline Forms.” The invention describes preparing a compound represented by Structural Formula (VII) by reacting compounds represented by Structural Formulas (II) and (III) in a solvent, using a palladium catalyst and one or more inorganic bases. It also covers crystalline Forms I and II of the compound, methods for preparing those forms, and their use in treating diseases or disorders associated with CRM1.

Career Highlights

Leduc’s listed patent reflects work on synthetic methods and crystalline forms of compounds with potential therapeutic applications. His company affiliation connects this work to Karyopharm Therapeutics Inc.

Collaborations

Leduc’s listed coworkers include Brian C. Austad and Stephen Edmund Gottschling. Their names appear alongside his in connection with the patent information provided.

Conclusion

Andrew Leduc’s patent work focuses on the synthesis and crystalline forms of a compound associated with potential CRM1-related treatments, reflecting his connection to pharmaceutical innovation at Karyopharm Therapeutics Inc.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…